The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism

Contraception. 2012 May;85(5):446-52. doi: 10.1016/j.contraception.2011.09.014. Epub 2011 Nov 12.

Abstract

Background: Combination oral contraceptives (OCs) have little effect on carbohydrate and lipid metabolism in normal-weight women. Based on lack of change in intermediate markers, as well as results of epidemiologic studies, low-dose OCs do not increase the risk of diabetes or cardiovascular disease. Obesity is a risk factor for impaired glucose tolerance, diabetes and coronary artery disease, and most previous OC studies excluded these women; thus, we have limited information about carbohydrate and lipid metabolism in obese OC users.

Study design: This study compared changes in carbohydrate and lipid parameters in 71 normal-weight and 38 obese women initiating the OC. Women were randomized to two pills: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG) or 20 mcg EE/100 mcg LNG. Participants underwent baseline and cycle-3 measurements of fasting serum glucose; insulin; triglycerides and total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

Results: Normal-weight and obese participants experienced similar changes in mean glucose, insulin and log homeostatic model assessment, as well as similar changes in total cholesterol, HDL and triglycerides; however, change in mean LDL (-4.9±20.6 mg/dL vs. +3.8±17.3 mg/dL) was different between the obese and normal-weight groups, respectively. Among the obese participants, change in glucose was marginally greater with the higher dose pill (p=.06); otherwise, changes between the body mass index groups were not modified by pill dose.

Conclusions: Obesity had little effect on any OC-induced changes in carbohydrate or lipid metabolism except for a borderline adverse interaction between obesity and OC dose with respect to fasting glucose and a positive interaction between obesity and OC use with respect to LDL cholesterol.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood
  • Blood Glucose / analysis
  • Body Mass Index
  • Carbohydrate Metabolism / drug effects*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Contraceptives, Oral, Combined / administration & dosage
  • Contraceptives, Oral, Combined / adverse effects*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Combinations
  • Ethinyl Estradiol / administration & dosage
  • Ethinyl Estradiol / adverse effects*
  • Female
  • Humans
  • Insulin / blood
  • Insulin Resistance
  • Levonorgestrel / administration & dosage
  • Levonorgestrel / adverse effects*
  • Lipid Metabolism / drug effects*
  • Medication Adherence
  • Obesity / blood
  • Obesity / metabolism*
  • Patient Dropouts
  • Triglycerides / blood
  • Young Adult

Substances

  • Biomarkers
  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Insulin
  • Triglycerides
  • ethinyl estradiol, levonorgestrel drug combination
  • Ethinyl Estradiol
  • Levonorgestrel